PolyNovo wins Company of the Year award
October 31 2019
PolyNovo has been named 'Company of the Year' in the AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards at AusBiotech 2019.Read more
October 27 2019
PolyNovo is delighted to announce the appointment of Dr Robyn Elliott to the board of directors as Non-Executive Director.Read more
May 6 2019
PolyNovo is delighted to announce the appointment of Mr Ashok Srinivasan to the position of Chief Operating Officer (“COO”), with responsibility for the Company’s operations, including manufacturing, engineering, supply chain and facilities.Read more
May 1 2019
PolyNovo has been granted access to the US Department of Defense (DoD) contracts through a Defense Acquisition and Program Administration (DAPA) and Veteran’s Affairs (VA) contract.
April 23 2019
PolyNovo is pleased to announce the first ever poster presentation detailing the use of NovoSorb BTM in Diabetic Foot and Venous Leg Ulcers.Read more
January 18 2019
PolyNovo wishes to announce the purchase of an adjoining office/warehouse facility. The intention is to combine the facilities and buildings allowing an expanded production facility suitable for several years.
December 12 2018
PolyNovo is pleased to announce the appointment of Mr Jan-Marcel Gielen as Chief Financial Officer and Company Secretary efffective 12 December.Read more
November 1 2018
PolyNovo is pleased to announce regulatory approval for the sale of NovoSorb BTM (NovoDerm) in India and the signing of Myovatec Surgical Systems Pvt Ltd (Myovatec) as its distributor.
August 2 2018
PolyNovo is pleased to announce that the last patient has been enrolled in the NovoSorb® Biodegradable Temporising Matrix (BTM) Full Thickness Burn feasibility clinical trial being conducted in the USA.
July 28 2018
PolyNovo is pleased to announce regulatory approval for NovoSorb BTM to be sold in Saudi Arabia and the signing of Al Mofadaly as its exclusive distributor.
July 26 2018
The Melbourne company PolyNovo Ltd has offered its life changing product for the use on burns victims in Greece. The company's NovoSorb® BTM has been offered to the surgical teams caring for patients burnt in the fires.
April 18 2018
PolyNovo congratulates Prof John Greenwood and Dr Marcus Wagstaff on winning “Best in Category- Wounds” for their Poster at the American Burn Association (ABA) meeting in Chicago.
April 3 2018
PolyNovo Ltd is pleased to announce the signing of the project plan for the development of a range of breast products with Establishment Labs (EL).Read more
March 20 2018
PolyNovo has been featured in the quarterly journal, the Australian Business Executive. A printed journal can be obtained through TheABE.com.au website/ subscription.Read more
June 2 2017
PolyNovo is pleased to announce that the Royal College of Surgeons (UK) have published Professor John Greenwood’s 2016 Hunterian Lecture. This paper outlines the evolution of burn care and the potential shift in patient care through the development of NovoSorb BTM (Biodegradable Temporizing Matrix).
May 12 2017
PolyNovo has been collaborating with Beta Cell Technologies Pty Ltd (“Beta Cell”) from Adelaide on a research project exploring the potential of integrated NovoSorb™ BTM to host pancreatic islets in the skin.
December 8 2016
Tony Lowther MD of Ascendis Medical attended the PolyNovo office for the signing of the agreement. It is great to have Tony and his Team working with PolyNovo.Read more
November 14 2016Read more
May 31 2016
ASX Announcement of the start of the BARDA funded feasibility trials in US.Read more